Parkinson's drug approved in new strength

August 13, 2007

A new strength of Stalevo, the combination drug from Orion Corp. and Novartis used to treat Parkinson's disease, has been approved by the FDA.

A new strength of Stalevo, the combination drug from Orion Corp. and Novartis used to treat Parkinson's disease, has been approved by the FDA. The 200-mg tablet will contain 50 mg carbidopa, 200 mg levodopa, and 200 mg entacapone and will offer physicians greater dosing flexibility for patients experiencing symptom reemergence due to end-of-dose "wearing off," according to the manufacturers. Stalevo is also available in 50-, 100-, and 150-mg strengths. The new 200-mg tablet will be available in pharmacies in October.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.